BERLIN, Germany -- Following the success of the Gibco™ Freedom™ CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific have teamed up again to develop an even better platform: the Gibco™ Freedom™ ExpiCHO-S™ Cell Line Development Kit. It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field. Applying its strong expertise in cell line and process development, ProBioGen has substantially contributed to the performance of the Freedom ExpiCHO-S Kit.
The new kit uses Thermo Fisher's ExpiCHO-S cell line and a new powerful media platform specifically developed for it. The kit is based on a novel set of ProBioGen vectors equipped with strong promoters, selection markers and protective elements providing expression stability. Together with a simple workflow optimized by ProBioGen, the kit provides short development time, reproducibly high titers (3-5 g/L) and high expression stability.
"Generating a stable and high performing cell line is the starting point for successful pharmaceutical development. The Gibco Freedom ExpiCHO-S Kit allows seamless transition from transient to stable production reproducing previously found product modifications. Moreover, the specific ProBioGen vector composition offers flexibility not only for antibodies but in particular for a variety of novel product formats", stated Dr. Volker Sandig, ProBioGen's Chief Scientific Officer.
The Gibco Freedom ExpiCHO-S Kit is sold by Thermo Fisher Scientific.
To find out more about ProBioGen and Thermo Fisher's collaboration on the new kit, and to get other ProBioGen updates, sign up for our newsletter to receive content including the Inside Bioprocessing podcast: 'Optimizing stable clone development to improve biopharmaceutical production'. Topics discussed in the podcast include the design and expression of plasmids; the expansion of desired clones for stable protein production; how to streamline this process; and the future of stable clone development.
